DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 21, 2022 16:05 ET
|
DICE Therapeutics, Inc.
On track to deliver topline proof-of-concept data from Phase 1 clinical trial of oral IL-17 antagonist DC-806 in healthy volunteers and psoriasis patients in mid-2022Named development candidate DC-853...
DICE Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 16:05 ET
|
DICE Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
DICE Therapeutics to Present at November Investor Conferences
November 16, 2021 16:05 ET
|
DICE Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
DICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent Highlights
November 12, 2021 08:00 ET
|
DICE Therapeutics, Inc.
Dosed first healthy volunteers in Phase 1 clinical trial of oral IL-17 antagonist S011806Successfully completed $234.6 million upsized initial public offering SOUTH SAN FRANCISCO, Calif., Nov. 12,...
DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis
October 25, 2021 08:00 ET
|
DICE Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
DICE Therapeutics Announces Pricing of Upsized Initial Public Offering
September 14, 2021 21:31 ET
|
DICE Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...